RYVU Therapeutics S.A. — M&A Activity 2025

Jan 29, 2025

Report Content Termination of STING program under Research Collaboration Option andExclusive License Agreement with BioNTech SE

The Management Board of Ryvu Therapeutics S.A., with its registeredoffice in Kraków, Poland ("Ryvu", the "Company"), informs that onJanuary 29, 2025, BioNTech SE, with its registered office in Mainz,Germany (_quot;BioNTech_quot;), notified the Company that for reasons relating tochange of BioNTech's portfolio strategy, the collaborator has decided toexercise its right to terminate the STING program covering Ryvu's STINGagonist portfolio as standalone small molecules ("STING Program";RVU312) along with two other of several previously undisclosed programs,which were implemented under the research collaboration and exclusivelicense agreement dated November 29, 2022 (_quot;License Agreement_quot;). Theconclusion of the License Agreement was disclosed by the Company in itsCurrent Report No. 26/2022, dated November 30, 2022.

As a result of the abovementioned termination, upon the expiration of3-months notice period, all licenses covering the terminated programsgranted by the Company to BioNTech under the License Agreement willexpire. Ryvu will regain full rights to the STING Program as standalonesmall molecules.

BioNTech and Ryvu will continue their multi-target researchcollaboration in the field of small molecule immunotherapy under theterms and conditions concluded in the License Agreement, including thefunding by BioNTech of all discovery, research and developmentactivities thereunder. The Company's financial projections consistentlyindicate that Ryvu's cash runway to Q1 2026 remains unchanged.